BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30217730)

  • 1. Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.
    Otano I; Escors D; Schurich A; Singh H; Robertson F; Davidson BR; Fusai G; Vargas FA; Tan ZMD; Aw JYJ; Hansi N; Kennedy PTF; Xue SA; Stauss HJ; Bertoletti A; Pavesi A; Maini MK
    Mol Ther; 2018 Nov; 26(11):2553-2566. PubMed ID: 30217730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model.
    Lee SWL; Adriani G; Ceccarello E; Pavesi A; Tan AT; Bertoletti A; Kamm RD; Wong SC
    Front Immunol; 2018; 9():416. PubMed ID: 29559973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
    Cheng Y; Gunasegaran B; Singh HD; Dutertre CA; Loh CY; Lim JQ; Crawford JC; Lee HK; Zhang X; Lee B; Becht E; Lim WJ; Yeong J; Chan CY; Chung A; Goh BKP; Chow PKH; Chan JKY; Ginhoux F; Tai D; Chen J; Lim SG; Zhai W; Choo SP; Newell EW
    Immunity; 2021 Aug; 54(8):1825-1840.e7. PubMed ID: 34270940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma.
    Gehring AJ; Ho ZZ; Tan AT; Aung MO; Lee KH; Tan KC; Lim SG; Bertoletti A
    Gastroenterology; 2009 Aug; 137(2):682-90. PubMed ID: 19394336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines.
    Gehring AJ; Xue SA; Ho ZZ; Teoh D; Ruedl C; Chia A; Koh S; Lim SG; Maini MK; Stauss H; Bertoletti A
    J Hepatol; 2011 Jul; 55(1):103-10. PubMed ID: 21145860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
    Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
    Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model.
    Tzeng HT; Tsai HF; Liao HJ; Lin YJ; Chen L; Chen PJ; Hsu PN
    PLoS One; 2012; 7(6):e39179. PubMed ID: 22761734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1
    Liu X; Li M; Wang X; Dang Z; Jiang Y; Wang X; Kong Y; Yang Z
    Cancer Immunol Immunother; 2019 Dec; 68(12):2041-2054. PubMed ID: 31720814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
    Tan AT; Schreiber S
    Antiviral Res; 2020 Apr; 176():104748. PubMed ID: 32087191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Lim CJ; Lee YH; Pan L; Lai L; Chua C; Wasser M; Lim TKH; Yeong J; Toh HC; Lee SY; Chan CY; Goh BK; Chung A; Heikenwälder M; Ng IO; Chow P; Albani S; Chew V
    Gut; 2019 May; 68(5):916-927. PubMed ID: 29970455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD40 activation rescues antiviral CD8⁺ T cells from PD-1-mediated exhaustion.
    Isogawa M; Chung J; Murata Y; Kakimi K; Chisari FV
    PLoS Pathog; 2013; 9(7):e1003490. PubMed ID: 23853599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD39
    Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
    Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient.
    Qasim W; Brunetto M; Gehring AJ; Xue SA; Schurich A; Khakpoor A; Zhan H; Ciccorossi P; Gilmour K; Cavallone D; Moriconi F; Farzhenah F; Mazzoni A; Chan L; Morris E; Thrasher A; Maini MK; Bonino F; Stauss H; Bertoletti A
    J Hepatol; 2015 Feb; 62(2):486-91. PubMed ID: 25308176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
    Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
    Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses.
    Zhang HH; Mei MH; Fei R; Liu F; Wang JH; Liao WJ; Qin LL; Wei L; Chen HS
    J Viral Hepat; 2010 Mar; 17 Suppl 1():34-43. PubMed ID: 20586932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
    Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
    Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.